Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jocn.2004.09.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diagnosis and Management of Progressive Corticobasal Syndrome.
Curr Treat Options Neurol
July 2024
Department of Neurology, Division of Behavioral Neurology, Stanford Neuroscience Health Center, 453 Quarry Road, Palo Alto, CA 94304, USA.
Purpose Of Review: The purpose of this review is to discuss the clinical, radiological, and neuropathological heterogeneity of corticobasal syndrome (CBS), which can complicate the determination of underlying etiology and lead to inaccurate treatment decisions. Though the most common diagnosis is corticobasal degeneration (CBD), the spectrum of underlying pathologies expands beyond CBD and can overlap with other neurodegenerative diseases and even the neuroimmunology field. We will review possible clinical presentations and cues that can point towards the etiology.
View Article and Find Full Text PDFSerum biomarkers as prognostic markers for Alzheimer's disease in a clinical setting.
Alzheimers Dement (Amst)
January 2025
Neurochemistry Laboratory Department of Laboratory Medicine Amsterdam UMC Amsterdam The Netherlands.
Introduction: Blood-based glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and phosphorylated tau (pTau) have shown promising prognostic potential in Alzheimer's disease (AD), but their applicability in clinical settings where comorbidities are prevalent remains uncertain.
Methods: Simoa assays quantified GFAP, NfL, and pTau181 in retrospectively retrieved prediagnostic serum samples from 102 AD patients and 21 non-AD controls.
Results: Higher serum GFAP levels predicted earlier clinical presentation and faster subsequent Mini-Mental State Examination decline in AD patients.
Evaluating conversion from mild cognitive impairment to Alzheimer's disease with structural MRI: a machine learning study.
Brain Commun
January 2025
Neuropsychiatry Laboratory, Department of Clinical Neuroscience and Neurorehabilitation, IRCCS Santa Lucia Foundation, Rome 00179, Italy.
Alzheimer's disease is a disabling neurodegenerative disorder for which no effective treatment currently exists. To predict the diagnosis of Alzheimer's disease could be crucial for patients' outcome, but current Alzheimer's disease biomarkers are invasive, time consuming or expensive. Thus, developing MRI-based computational methods for Alzheimer's disease early diagnosis would be essential to narrow down the phenotypic measures predictive of cognitive decline.
View Article and Find Full Text PDFBlocking the adverse outcome pathway of skin sensitization through a -acetyl cysteine and lysine-loaded hydrogel.
J Pharm Anal
January 2025
Faculty of Pharmacy, University of Coimbra, 3000-548, Coimbra, Portugal.
Image 1.
View Article and Find Full Text PDFThe Need for IRB Leadership to Address the New Ethical Challenges of Research with Highly Portable Neuroimaging Technologies.
J Law Med Ethics
January 2025
UNIVERSITY OF MINNESOTA, MINNEAPOLIS, MN, USA.
The emergence of innovative neuroimaging technologies, particularly highly portable magnetic resonance imaging (pMRI), has the potential to spawn a transformative era in neuroscience research. Resourced academic institutional review boards (IRBs) with experience overseeing traditional MRI have a special role to play in ethical governance of pMRI research and should facilitate the collaborative development of nuanced and culturally sensitive guidelines and educational resources for pMRI protocols. This paper explores the ethical challenges of pMRI in neuroscience research and the dynamic leadership role that IRBs should play to promote ethical oversight of emerging pMRI research.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!